• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

MS Contin (morphine sulfate) controlled-release tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010

 

Summary View

 

ADVERSE REACTIONS

Less Frequently Observed Reactions
  • malaise, thinking disturbances, vertigo